Literature DB >> 26934938

Silencing of CerS6 increases the invasion and glycolysis of melanoma WM35, WM451 and SK28 cell lines via increased GLUT1-induced downregulation of WNT5A.

Yuanyuan Tang1, Ke Cao2, Qi Wang2, Jia Chen1, Rui Liu1, Shaohua Wang1, Jianda Zhou1, Huiqing Xie3.   

Abstract

Ceramide synthases (CerSs) have been shown to regulate numerous aspects of cancer development. CerS6 has been suggested to be involved in cancer etiology. However, little is known concerning the exact effect of CerS6 on the malignant behavior of melanoma, including glycolysis, proliferation and invasion. In the present study, we found that the expression of CerS6 was low in the melanoma cell lines, including WM35, WM451 and SK-28, and the expression level was related to the malignanct behavior of the melanoma cell lines. We constructed overexpression and silencing models of CerS6 in three melanoma cell lines and found that silencing of CerS6 promoted the ability of proliferation and invasion in the melanoma cell lines. Additionally, downregulation of CerS6 upregulated the activity of glycolysis-related enzyme, and enhanced the expression of glycolysis-related genes, including GLUT1 and MCT1. Furthermore, we identified the genes whose expression levels were changed after silencing of CerS6 by gene microarray. The expression of glycolysis-related gene SLC2A1 (also known as GLUT1) was found to be upregulated, while notably WNT5A was downregulated. The altered expression of GLUT1 and WNT5A was verified by qPCR and western blotting. Furthermore, silencing of GLUT1 in the melanoma cells resulted in the increased expression of WNT5A and the decreased ability of invasion and proliferation in the melanoma cells. Collectively, silencing of CerS6 induced the increased expression of GLUT1, which downregulated the expression of WNT5A and enhanced the invasion and proliferation of melanoma cells. Thus, CerS6 may provide a novel therapeutic target for melanoma treatment.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26934938     DOI: 10.3892/or.2016.4646

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

Review 1.  Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer.

Authors:  Christina Voelkel-Johnson; James S Norris; Shai White-Gilbertson
Journal:  Adv Cancer Res       Date:  2018-06-20       Impact factor: 6.242

2.  C16:0 ceramide effect on melanoma malignant behavior and glycolysis depends on its intracellular or exogenous location.

Authors:  Rui Liu; Ke Cao; Yuanyuan Tang; Jinyan Liu; Jingjing Li; Jia Chen; Shaohua Wang; Zizi Chen; Jianda Zhou
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

3.  Adoptive Transfer of Ceramide Synthase 6 Deficient Splenocytes Reduces the Development of Colitis.

Authors:  Matthew J Scheffel; Kristi Helke; Ping Lu; Jacob S Bowers; Besim Ogretmen; Elizabeth Garrett-Mayer; Chrystal M Paulos; Christina Voelkel-Johnson
Journal:  Sci Rep       Date:  2017-11-14       Impact factor: 4.379

4.  Comprehensive analysis of LASS6 expression and prognostic value in ovarian cancer.

Authors:  Jinshan Xing; Jingyan Yi
Journal:  J Ovarian Res       Date:  2021-09-07       Impact factor: 4.234

5.  Nuclear Transport Factor 2 (NTF2) suppresses WM983B metastatic melanoma by modifying cell migration, metastasis, and gene expression.

Authors:  Lidija D Vuković; Pan Chen; Sampada Mishra; Karen H White; Jason P Gigley; Daniel L Levy
Journal:  Sci Rep       Date:  2021-12-08       Impact factor: 4.379

6.  Exercise Promotes Pro-Apoptotic Ceramide Signaling in a Mouse Melanoma Model.

Authors:  Jonghae Lee; Hannah Savage; Shinji Maegawa; Riccardo Ballarò; Sumedha Pareek; Bella Samia Guerrouahen; Vidya Gopalakrishnan; Keri Schadler
Journal:  Cancers (Basel)       Date:  2022-09-02       Impact factor: 6.575

Review 7.  New Insights into the Role of Sphingolipid Metabolism in Melanoma.

Authors:  Lorry Carrié; Mathieu Virazels; Carine Dufau; Anne Montfort; Thierry Levade; Bruno Ségui; Nathalie Andrieu-Abadie
Journal:  Cells       Date:  2020-08-26       Impact factor: 6.600

Review 8.  Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives.

Authors:  Laurence Pellerin; Lorry Carrié; Carine Dufau; Laurence Nieto; Bruno Ségui; Thierry Levade; Joëlle Riond; Nathalie Andrieu-Abadie
Journal:  Cancers (Basel)       Date:  2020-10-27       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.